[adrotate group="2"]

BIOTECH STOCKS EXPLODE! CRMD SOARS 19% IN ONE DAY!

Are you ready for the wildest ride in the biotech world? Buckle up because CorMedix (CRMD) just dropped some explosive news that sent its stock soaring by a staggering 19.40% today! 💥🔥 But don’t let the hype sweep you off your feet—there’s more to this thrilling tale!

CORMEDIX IS CRUSHING EXPECTATIONS!

In a jaw-dropping revelation, CorMedix announced preliminary Q1 2025 results, revealing an unaudited net revenue of $39 million! That’s right, folks! They smashed expectations and if that’s not enough, hold onto your hats because the adjusted EBITDA is expected to rocket past $22.5 million when the final figures roll in!

But wait, there’s more! CorMedix has upped its game by raising the first half 2025 guidance to a jaw-dropping $62 million to $70 million. This bump is fueled by colossal orders from eager customers that came flying in March. 🚀 Is this the start of a biotech boom?

A WARNING FOR INVESTORS: DON’T GET CAUGHT IN THE HYPE!

While today’s surge is enough to make your heart race, savvy investors should proceed with caution! Just because CRMD is basking in the limelight doesn’t mean it’s out of the woods. Remember, the biotech jungle is full of twists and turmoil! ⚠️

Sure, their flagship product, DefenCath, appears promising, but the history of biotech is littered with cautionary tales of setbacks and surprises. So, keep your eyes peeled, folks!

STOCK VOLATILITY: A CRUCIAL CONCERN!

CRMD has shown wild volatility over the past year, with prices bouncing all over the place from $3.61 to $13.85 per share. So, while today’s spectacular gains might feel exhilarating, history often points to a potential pullback.

KEY TAKEAWAYS YOU CAN’T IGNORE!

• CorMedix boasts an impressive $39 million net revenue for Q1 2025.
• Adjusted EBITDA soaring above $22.5 million.
• Rocked-up guidance for first half 2025 to $62-70 million, driven by March orders!
• CRMD stock just erupted by 19.40% today!

WHAT’S NEXT? KEEP YOUR FINGER ON THE PULSE!

Investors, stay sharp! Keep a hawk’s eye on CorMedix’s commercialization strategy and how its inventory holds up. There’s no denying that DefenCath has potential, but it’s a rough ride in biotech! If you’re thinking of adding CRMD to your treasure trove, make sure you’re ready for some real volatility.

STAY IN THE LOOP!

Don’t miss out on the latest thrilling updates in the market! Sign up for our free daily SMS alerts now and stay ahead of the game! 📈✨